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Meta-analysis of existing genome-wide association studies on Alzheimer’s disease (AD) showed
subgenome-wide association of an intronic variant in the sequestosome 1 (SQSTM1) gene with AD. We
performed targeted resequencing of SQSTM1 in Flanders-Belgian AD patients selected to be enriched for a
genetic background (n ¼ 435) and geographically matched nonaffected individuals (n ¼ 872) to inves-
tigate the role of both common and rare SQSTM1 variants. Results were extended to the European early-
onset dementia cohorts (926 early-onset Alzheimer’s disease [EOAD] patients and 1476 nonaffected
individuals). Of the 61 detected exonic variants in SQSTM1, the majority were rare (n ¼ 57). Rare variant
(minor allele frequency <0.01) burden analysis did not reveal an increased frequency of rare variants in
EOAD patients in any of the separate study populations nor when meta-analyzing all cohorts. Common
variants p.D292¼ and p.R312¼ showed nominal association with AD (odds ratiop.D292¼ ¼ 1.11 [95%
conﬁdence interval ¼ 1e1.22], p ¼ 0.04), only when including the Flanders-Belgian cohort in the meta-
analysis. We cannot exclude a role of SQSTM1 genetic variability in late-onset AD, but our data indicate
that SQSTM1 does not play a major role in the etiology of EOAD.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mega meta-analysis of existing genome-wide association
studies (GWAS) on Alzheimer’s disease (AD) performed by the
International Genomics of Alzheimer’s Project identiﬁed an
intronic variant in the sequestosome 1 (SQSTM1) gene, which
showed subgenome-wide association with AD (rs72807343, odds
ratio [OR] ¼ 1.35 [95% conﬁdence interval {CI} ¼ 1.20e1.52], p ¼
7  107) (Lambert et al., 2013). SQSTM1 encodes the p62 protein
that is a stress-responsive ubiquitin-binding protein commonly
found in neuronal cytoplasmic inclusions in protein aggregation
diseases like AD, Parkinson disease, Pick disease, etc. (Kuusisto
et al., 2001; Zatloukal et al., 2002). P62 is involved in protein
degradation via the proteasome, in protein aggregation, and in
autophagy (Bjorkoy et al., 2006; Seibenhener et al., 2004). Mu-
tations in this gene, especially affecting the ubiquitin-associated
(UBA) domain of the p62 protein, have been found to be the
most common cause of Paget disease of the bone (PDB), a disease
that is characterized by malformed bones (Johnson-Pais et al.,
2003). Using a hypothesis-driven candidate gene approach, a
direct genetic role for SQSTM1 in both familial and sporadic
amyotrophic lateral sclerosis was identiﬁed in a European-
American population (Fecto et al., 2011). Screening of addi-
tional amyotrophic lateral sclerosis (ALS) populations led to the
identiﬁcation of novel variations in the gene (Hirano et al., 2013;
Teyssou et al., 2013). These results suggested that presumably
ALS and PDB share a common molecular pathomechanism
(Hirano et al., 2013), reminiscent of PDB, and frontotemporal
lobar degeneration (FTLD) in VCP mutation carriers (Kimonis
et al., 2008; Watts et al., 2007; van der Zee et al., 2009). Add-
ing to the ﬁrmly established clinicopathologic relationship be-
tween ALS and FTLD, studies were conducted to investigate the
frequency of SQSTM1 variants in FTLD patients (Rubino et al.,
2012; van der Zee et al., 2014). Rare mutations clustering in
the UBA domain of p62 were found to be associated with a 2-
fold increased risk to develop FTLD (Rubino et al., 2012; van
der Zee et al., 2014).
In this study, we investigated the contribution of both rare and
common variations in the SQSTM1 exonic region to the occurrence of
AD in a cohort of Flanders-BelgianADpatients selected to be enriched
for a genetic background (early disease onset and/or familial AD,
n ¼ 435) and geographically matched nonaffected individuals
(n ¼ 872). Our results were extended to a European early-onset de-
mentia (EU EOD) cohort comprising 926 early-onset Alzheimer’s
disease (EOAD) patients and 1476 nonaffected individuals.2. Materials and methods
2.1. Study population
2.1.1. Flanders-Belgian cohort
We selected 435 AD patients with early-onset age (age of onset
[AAO] <65 years) and/or familial disease (at least one ﬁrst-degree
relative with the disease) (mean AAO ¼ 67.7  8.2 years,
women ¼ 62.2%) from a large prospective cohort of Belgian AD
patients ascertained at the Memory Clinic of the ZNA Middelheim
and Hoge Beuken, Antwerp, Belgium (PPDD and SE) (Engelborghs
et al., 2003, 2006) and the Memory Clinic of the University Hospi-
tals of Leuven, Leuven, Belgium (MV and RV) (Table 1). Consensus
diagnosis of possible and probable AD was given by at least 2
neurologists based on the National Institute of Neurological and
Communication Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association criteria (McKhann et al., 1984,
2011). Each patient underwent a neuropsychological examination
and structural and/or functional neuroimaging (Bettens et al.,
2009).
The Flanders-Belgian control cohort (n ¼ 872, mean age at
inclusion ¼ 66  12.7 years, women ¼ 55.6%) consisted pri-
marily of community-dwelling volunteers, for whom subjective
memory complaints, neurologic or psychiatric antecedents, and
a familial history of neurodegeneration were ruled out by means
of an interview. Cognitive screening was performed using the
Mini-Mental State Examination (cutoff score 26) (Folstein
et al., 1975). The control cohort additionally included spouses
of patients, examined at the Memory Clinic of ZNA Middelheim
and Hoge Beuken, Antwerp, Belgium and the Memory Clinic at
the University Hospitals of Leuven, Gasthuisberg, Leuven,
Belgium.
All participants and/or their legal guardian gave written
informed consent for participation in clinical and genetic studies.
Clinical study protocol and the informed consent forms for patient
ascertainment were approved by the ethics committee of the
respective hospitals at the cohort sampling sites in Belgium. The
genetic study protocols and informed consent formswere approved
by the Ethics Committees of the University of Antwerp and the
University Hospital of Antwerp, Belgium.
2.1.2. EU EOD cohort
Patients and control individuals ascertained through the EU
EOD consortium were included as replication cohort (van der Zee
et al., 2013, 2014). For this study, DNA and medical/demographic
Table 1
All exonic variants in SQSTM1 that were identiﬁed in the Flanders-Belgian cohort
Exonic
variants
Protein domain Genomic position Protein
position
dbSNP137 Minor allele
count AD
Freq AD OR (95% CI),
p value
Minor allele
count control
Freq
control
Freq EVS
Exon 1 PB1 g.179248023C>G p.P29¼ 0 0.000 2 0.001 d
PB1 g.179248034C>T p.A33V rs200396166 1 0.001 0 0.000 0.0008
PB1 g.179248119C>T p.G61¼ 1 0.001 2 0.001 d
Exon 3 PB1<>ZZ g.179250885G>A p.R110H 0 0.000 1 0.001 d
PB1<>ZZ g.179250906C>T p.A117V rs147810437 0 0.000 2 0.001 0.0012
PB1<>ZZ g.179250930A>G p.N125S 0 0.000 1 0.001 d
ZZ g.179251013G>A p.V153I rs145056421 1 0.001 3 0.002 0.001
Exon 4 ZZ<>TRAF6 g.179251313G>A p.T221¼ 0 0.000 1 0.001 d
Exon 5 TRAF6 g.179252168G>A p.P232¼ rs145688323 1 0.001 0 0.000 0
TRAF6 g.179252184A>G p.K238E rs11548633 8 0.009 7 0.004 0.0035
Exon 6 PEST1 g.179260072A>C p.R265S 0 0.000 1 0.001 d
PEST1 g.179260073A>C p.S266R 0 0.000 1 0.001 d
PEST1 g.179260099G>C p.E274D rs55793208 21 0.025 1.67 (0.91e3.05), 0.096 31 0.018 0.0253
PEST1 g.179260110C>T p.T278I rs200445838 0 0.000 1 0.001 d
PEST1 g.179260153C>T p.D292[ rs4935 489 0.575 1.22 (1.01e1.47), 0.035 933 0.535 0.5294
PEST1<>LIR g.179260165G>A p.P296¼ rs148984239 0 0.000 1 0.001 0.0001
PEST1<>LIR g.179260183C>T p.G302¼ rs11548642 1 0.001 1 0.001 0.0002
PEST1<>LIR g.179260202G>A p.A308¼ 0 0.000 1 0.001 d
PEST1<>LIR g.179260213G>A p.R312[ rs4797 479 0.564 1.23 (1.02e1.48), 0.03 920 0.528 0.5227
PEST1<>LIR g.179260231C>T p.S318¼ rs56092424 20 0.024 1.56 (0.85e2.89), 0.151 31 0.018 0.0212
PEST1<>LIR g.179260232G>A p.E319K rs61748794 0 0.000 1 0.001 0.0002
Exon 7 LIR g.179260601G>A p.S328¼ rs146164139 5 0.006 11 0.006 0.0045
LIR<>PEST2 g.179260649A>G p.K344¼ d 0 0.000 3 0.002 d
PEST2 g.179260661G>A p.P348¼ rs10058037 0 0.000 1 0.001 0.0002
PEST2 g.179260700C>T p.S361¼ rs201591177 1 0.001 0 0.000 0.0001
Exon 8 UBA g.179263445C>T p.P392L rs104893941 2 0.002 4 0.002 0.0021
UBA g.179263543G>A p.G425R 0 0.000 1 0.001 d
UBA g.179263544G>A p.A426¼ 0 0.000 2 0.001 d
UBA g.179263583C>T p.P438L 2 0.002 0 0.000 d
UBA g.179263586C>T p.P439L 0 0.000 1 0.001 d
SQSTM1 (NM_003900.4). Genomic position in base pairs according to hg19 (GRCh37), and “d” denotes not applicable. Total allele count for the Belgian population is 870 AD
and 1744 control alleles. A comparison of frequencies with those in EVS in European samples (at least 7388 alleles) is provided. The variations with MAF >1% and signiﬁcant p
values are indicated in bold. Chi2 p values are corrected for AAO, gender, and APOE genotype. Protein domains are based on UniProt information; transcript level on
NM_003900.4, and protein level on the GenPept Accession Number NP_003891.1. Protein domains were assigned as described previously (van der Zee et al., 2014). “<>”
denotes between protein domains. Rare nonsynonymous variants p.P438L and p.A33V were present in the same AD patient (female, AAO ¼ 75 years). In addition, variants
p.R265S and p.S266R were identiﬁed in the same control individual (male, AAI ¼ 70 years).
Key: AAO, age at onset; AD, Alzheimer’s disease; EVS, Exome Variant Server; freq, frequency; MAF, multiple allele frequency; OR, odds ratio; SQSTM1, sequestosome 1; TRAF6,
tumor necrosis factor receptoreassociated factor 6; UBA, ubiquitin associated.
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originating from Spain (n ¼ 329), Portugal (n ¼ 107), Italy (n ¼
210), Sweden (n ¼ 175), Germany (n ¼ 98), and Czech Republic
(n ¼ 7), was contributed by members of the consortium
(Supplementary Table 1). Patients were diagnosed following the
National Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related Disorders
Association International Working Group criteria (McKhann et al.,
1984, 2011). Diagnosis of pathology conﬁrmed patients was based
on currently accepted diagnostic criteria (Montine et al., 2012).
Genetic proﬁling of AD-associated genes was previously generated
for a subset of patients APP (n ¼ 227), presenilin-1 (PSEN1) (n ¼
248), PSEN2 (n ¼ 225), GRN (n ¼ 11), and MAPT (n ¼ 11)
(Supplementary Materials and Methods). This revealed 3 APP, 14
PSEN1, and 5 PSEN2 missense mutations and 1 GRN frameshift
mutation. Genotyping of APOE was performed in the total patient
population.
As control group, we sequenced 1476 age- and origin-matched
European individuals (Spain [n ¼ 484], Portugal [n ¼ 127], Italy
[n ¼ 518], Sweden [n ¼ 340], and Czech Republic [n ¼ 7]) tested for
normal cognition for age and education and Mini-Mental State
Examination cutoff score>26. For all EU EOD participants, informed
consent for participation, approved by the ethics committee of the
respective hospitals or sampling sites, was obtained. A more
detailed description of the EU EOD consortium cohort can be found
in the Supplementary Table 1.2.2. SQSTM1 sequencing
For the Flanders-Belgian cohort, genomic DNA was extracted
from peripheral blood lymphocytes using MagDEA DNA Whole-
Blood (8Lx) kit (Precision System Science, Pleasanton, CA, USA).
Resequencing of the full SQSTM1 exonic DNA sequence (coding
sequence [CDS]) of the Flanders-Belgian sample (n ¼ 1307) was
performed by polymerase chain reaction (PCR)ebased ampliﬁca-
tion of DNA followed by Sanger sequencing of the 8 exons and
intron-exon boundaries (NM_003900.4). Primers were designed
using the PCR primer design tool Primer3 (primer sequences are
available on request, http://primer3.sourceforge.net/). All se-
quences were analyzedwith Seqman (DNASTAR, Madison,WI, USA)
and NovoSNP software packages (Reumers et al., 2011;Weckx et al.,
2005).
For the EU EOD cohort, DNA samples were subjected to quality
control procedures as previously described (van der Zee et al.,
2014). Resequencing of SQSTM1 was performed by massive paral-
lel resequencing after multiplex amplicon enrichment. To this end,
we designed a target enrichment assay based onMASTR technology
(Multiplicom, Niel, Belgium) covering SQSTM1 coding exons 2e8,
ﬂanking intron-exon boundaries and untranslated regions. SQSTM1
exon 1 was screened by Sanger sequencing as described previously.
Primers for multiplex PCR were designed using mPCR (Multi-
plicom). Multiplex PCR was performed for ampliﬁcation of the
target region, followed by puriﬁcation of the equimolar pooled
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Coulter, CA, USA). Patient-speciﬁc barcodes (Illumina Nextera XT)
were incorporated in a universal PCR step. Barcoded samples were
pooled before bridge ampliﬁcation and sequencing on an Illumina
MiSeq platform, using the Illumina reagent kit v2, generating 250-
bp paired-end reads. A subset of the control cohort (n ¼ 707) was
screened using both MASTR massive parallel resequencing and
Sanger sequencing. This dual analysis showed a high concordance
of 99.4% between both used technologies.
Fastq-mcf was used to trim the MiSeq (Illumina) adapters of the
paired-end reads. Alignment and mapping of the reads against the
whole genome (hg19) was performed with Burrows-Wheeler
Aligner (Li and Durbin, 2009). Variant calling and annotation was
performed using GATK, version 2.2 (McKenna et al., 2010) in com-
bination with GenomeComb software (Reumers et al., 2011). Raw
reads of rare variants were manually checked using the integrative
genomics viewer (IGV; Broad Institute, Cambridge, MA, USA). Rare
variants were validated on genomic DNA using Sanger sequencing.
Numbering of variations at genomic DNA level was based on the
GenBank Accession Number NC_000005.9, transcript level on
NM_003900.4, and protein level on the GenPept Accession Number
NP_003891.1.
2.3. In silico prediction
The effects of coding SQSTM1 variations were predicted using
Polymorphism Phenotyping (PolyPhen-2, version 2, http://genetics.
bwh.harvard.edu/pph2/), Sorting Intolerant from Tolerant (SIFT,
http://sift.jcvi.org/www/SIFT_enst_submit.html), and SNPs&Go
(http://snps.uib.es/snps-and-go//snps-and-go.html). PolyPhen-2
predicts a possible impact of amino acid substitutions on the
structure and function of human proteins. The Polyphen-2 score
ranges from 0 to 1 and indicates the probability of a damaging ef-
fect. SIFT predicts whether an amino acid substitution affects pro-
tein function based on sequence homology and physical
proportions of amino acids. A SIFT score <0.05 suggests pathoge-
nicity. SNPs&Go predicts human diseaseerelated mutations in
functionally annotated proteins. The reliability index reports the
reliability of the prediction, scoring from 0 (unreliable) to 10 (reli-
able). If the disease probability is >0.5, the variation is predicted as
disease associated. MutationTaster was used to predict the effect of
synonymous variants (Schwarz et al., 2014). If the probability value
is close to 1, this indicates a high certainty of the prediction.
2.4. Statistical analyses
For common SQSTM1 variants with minor allele frequency
(MAF) >1%, deviations from Hardy-Weinberg equilibrium were
assessed using an exact Hardy-Weinberg equilibrium test (www.
pharmgat.org/IIPGA2/Bioinformatics/exacthweform), and allele
frequencies were compared between AD patients and healthy
control individuals using c2 statistics. ORs (calculated relative to the
common genotype) and 95% CIs were calculated using a logistic
regression model, using SPSS, version 20.0, for Windows (IBM SPSS
Inc, Chicago, IL, USA), corrected for onset age (AAO), gender, and
APOE ε4. A 2-sided p-value of 0.05 was considered statistically
signiﬁcant. Fixed-effects (Mantel-Haenszel) meta-analysis of the
common variants was performed based on raw allele data of the
different EU EOD cohorts. The Czech (7 patients and 7 control in-
dividuals) and German (patients only) cohorts were not included in
the association analysis. Mantel-Haenszel summary OR and Woolf
test for heterogeneity were computed in R using the library rmeta,
version 2.16. We performed rare variant burden analysis on the
cumulative frequency of nonsynonymous variant alleles with MAF
<1% either spanning the full exonic region of SQSTM1 or affectingdifferent protein domains using c2 statistics. As for the common
variants, meta-analysis (Mantel-Haenszel) of rare variant alleles
was performed, following the same procedures as described earlier.
Protein domains were assigned as described previously (van der
Zee et al., 2014).
3. Results
3.1. SQSTM1 mutation screening in the Flanders-Belgian cohort
Sequencing of the SQSTM1 CDS in the Flanders-Belgian cohort
resulted in the identiﬁcation of 26 rare variants (MAF <0.01), of
which 14 variations were nonsynonymous (Table 1). Two of these
variants (p.A33V and p.P438L) were absent from 872 Belgian con-
trol individuals. The amino acid substitution p.P438L, located in the
C-terminal region of the UBA domain of the protein and predicted
to be damaging for protein structure and/or function, was previ-
ously described in a patient with ALS (Rubino et al., 2012). The
mutation was found in 2 AD patients with onset ages of 67 and 75
years. The 2 AD patients shared a second nonsynonymous variation,
p.E274D, which is a low-frequency variant (MAF 0.025). The AD
patient with AAO of 75 years also carried a third rare non-
synonymous variant, which is the other variant that was absent
from control individuals, that is, p.A33V. This variant is located in
the ﬁrst exon of SQSTM1, encoding the Phox and Bem1p (PB1)
domain. This variation was absent from our Flanders-Belgian con-
trol cohort, but has been reported before at low frequency in public
databases, and is predicted benign based on impact on protein
structure and function (Supplementary Table 3). Review of clinical
records of both patients did not show evidence of ALS or PDB,
although on X-ray of the skull of the patient with AAO of 75 years, a
diploic skull was noted. Further, 2 synonymous variants (p.P232¼
and p.S361¼) were found in patients only located in tumor necrosis
factor receptoreassociated factor 6 (TRAF6) and proline (P), gluta-
mic acid (E), serine (S), and threonine (T) (PEST2) domains. Sixteen
variants were observed in control individuals only, of which 9 were
nonsynonymous.
3.2. Rare variant association analysis in the Flanders-Belgian cohort
No signiﬁcant difference in total number of rare variations (MAF
<0.01) was identiﬁed between the Belgian AD (14/870¼ 0.016) and
control individuals (24/1744 ¼ 0.014) (relative risk [RR] ¼ 0.94 [95%
CI ¼ 0.57e1.55], allelic p ¼ 0.8) (Table 2). When investigating rare
variant burden in the different functional protein domains of
SQSTM1, we did not observe a signiﬁcant increase in rare variants in
speciﬁc domains in AD patients versus control individuals. The low-
frequent variant p.E274D (and p.S318¼, in strong LD) was observed
slightly more often in patients (MAF 0.025) than control individuals
(MAF 0.018), but this did not reach statistical signiﬁcance (OR¼ 1.67
[95% CI ¼ 0.91e3.05], allelic p ¼ 0.096). Inclusion of this variant in
the whole gene burden analysis (RR ¼ 1.16 [95% CI ¼ 0.91e1.49],
allelic p¼ 0.23) or analysis of the PEST1 domain (RR ¼ 1.2 [95% CI ¼
0.72e2.16], allelic p¼ 0.44) inwhich it is located did not change the
observations.
3.3. Association of common SQSTM1 variants in the Flanders-
Belgian cohort
Two common polymorphisms with MAF >0.05 were observed in
the CDS of SQSTM1, both synonymous (p.D292¼ andp.R312¼). Allelic
association with AD was observed for both variants p.D292¼ (OR ¼
1.22 [95% CI ¼ 1.01e1.46], allelic p ¼ 0.037) and p.R312¼ (OR ¼ 1.23
[95% CI ¼ 1.02e1.48], allelic p ¼ 0.03) that are in strong pairwise
linkage disequilibrium (HapMap D’ ¼ 0.915 in Centre d’Etude du
Table 2
Whole-gene rare variant burden analysis per country
Country Rare alleles/total alleles AD patients Rare alleles/total alleles control individuals Fisher exact (p value)
Belgium 14/870 (1.6%) 24/1744 (1.4%) 0.61
Spain 15/658 (2.3%) 21/968 (2.2%) 0.87
Italy 10/420 (2.4%) 11/1036 (1.1%) 0.09
Portugal 5/214 (2.3%) 6/254 (2.4%) 1.00
Sweden 6/350 (1.7%) 6/680 (0.9%) 0.24
Meta-analysis 50/2512 (2%) 68/4682 (1.5%) OR ¼ 1.32 (95% CI ¼ 0.91e1.91)
p value ¼ 0.14
Heterogeneity e p value ¼ 0.6
All nonsynonymous rare alleles were taken into account to perform the burden analysis. Fisher exact 2-tailed p values are shown for the individual populations. Mantel-
Haenszel summary OR and Woolf test for heterogeneity are shown for the meta-analysis of the 5 cohorts.
Key: AD, Alzheimer’s disease; CI, conﬁdence interval; OR, odds ratio.
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ern and western Europe] [CEU] population). Conditional logistic
regression was performed to investigate if the observed association
between AD and these common variants was mediated by the
borderline effect of the low-frequency variant p.E274D (OR ¼ 1.22
[95% CI¼ 1.01e1.47], nominal allelic p¼ 0.04) or the presence of rare
alleles (OR ¼ 1.23 [95% CI ¼ 1.02e1.49], nominal allelic p ¼ 0.034).
None of these conditions could affect the association with AD.
3.4. Replication analyses in the EU EOD cohort
To increase power to interpret the ﬁndings of the Flanders-
Belgian AD cohort, we extended our analysis to the EU EOD
cohort, including 926 patients and 1476 control individuals origi-
nating from Spain, Portugal, Italy, Sweden, Germany, and Czech
Republic. In total, 48 variations, both synonymous and non-
synonymous, were identiﬁed in the exonic sequence of the SQSTM1
gene. Of these, 44 variants were rare (MAF<1%) of which 23 caused
a change at the protein level, 4 in AD patients only, 9 in controls
only, and 10 in both patients and controls (Fig. 1, Supplementary
Tables 2 and 3). Of the 4 variants that were only identiﬁed in AD
patients and excluded from the tested control population, 2 vari-
ants were never described before in the context of PDB, ALS, or
FTLD: p.P29S and p.L268V (Table 3). The patient carrying the p.P29S
mutation also carried a second SQSTM1 variant (p.A117V) and a
pathogenic mutation in the PSEN1 (p.L392V) gene, which most
likely explain the early onset age of 40 years. Furthermore, the AD
patient who carried the p.L268V mutation also carried anotherFig. 1. Nonsynonymous sequestosome 1 (SQSTM1) mutations identiﬁed in Alzheimer’s disea
onset dementia consortium. Protein domains are indicated (transcript level on NM_003900
were assigned as described previously (van der Zee et al., 2014). PB1, PhoX and Bem1P; ZZ,
regions rich in proline, glutamate, serine, and threonine; LIR, LC3-interacting region; and UB
study are indicated in red. Variants that were only identiﬁed in control individuals (n ¼ 15)
individuals (n ¼ 12) are indicated in black.mutation (p.P397L) that was also excluded from the control pop-
ulation but was earlier described in context of PDB.
Rare variant (MAF <0.01) burden analysis did not reveal an
increased frequency of rare variants in SQSTM1 in EOAD patients in
any of the separate study populations nor when meta-analyzing all
EU EOD cohorts of the consortium (OR ¼ 1.39 [95% CI ¼ 0.89e2.17],
p ¼ 0.14) (Table 2). Inclusion of the Flanders-Belgian cohort in the
meta-analysis did not change the outcome (OR ¼ 1.32 [95% CI ¼
0.91e1.91], p ¼0.14) (Table 2). Furthermore, we found no evidence
of predominant clustering of disease-causing alleles in speciﬁc
protein domains in separate cohorts or in a meta-analysis with or
without inclusion of the Flanders-Belgian cohort (data not shown).
Meta-analysis of the low-frequent variant p.E274D (and p.S318¼, in
strong LD) in the different EU EOD cohorts did not reach statistical
signiﬁcance (ORp.E274D ¼ 0.9 [95% CI ¼ 0.6e1.34], allelic p ¼ 0.59).
Inclusion of this variant in the whole-gene burden meta-analysis of
the Flanders-Belgian and EU EOD cohorts (OR ¼ 1.14 [95% CI ¼
0.89e1.46], allelic p ¼ 0.28) did not change the observations.
Remarkably, 17 of 29 synonymous variants were predicted to be
“disease causing” by MutationTaster. However, inclusion of these
variants in the rare variant meta-analysis did not show evidence of
association with AD (OR ¼ 1.15 [95% CI ¼ 0.87e1.53], allelic p ¼
0.32). The common variants p.D292¼ and p.R312¼ showed asso-
ciation with AD (ORp.D292¼ ¼ 1.11 [95% CI ¼ 1e1.22], nominal p ¼
0.04) (Fig. 2) but only when including the Flanders-Belgian cohort.
Meta-analysis excluding the Flanders-Belgian cohort did not show
evidence of association (ORp.D292¼ ¼ 1.07 [95% CI ¼ 0.95e1.21], p ¼
0.27).se (AD) and control cohorts from Flanders-Belgian population and the European early-
.4 and protein level on the GenPept Accession Number NP_003891.1). Protein domains
zinc ﬁnger (zz type); TRAF6, tumor necrosis factor receptoreassociated factor 6; PEST,
A, ubiquitin associated. Variants that were only identiﬁed in AD patients (n ¼ 5) in our
in our study are indicated in blue. Variants identiﬁed in both AD patients and control
Table 3
SQSTM1 mutations present in patients and absent from the control cohorts that were screened for this study
Mutation Functional domain Origin Gender Clinical diagnosis Family history Age at onset (y) Previously reported
p.P29Sa PB1 Italy f Deﬁnite AD S 40 No
p.L268V PEST1 Italy f Probable AD S 58 No
p.P387L UBA Italy f Probable AD S 58 FTLD/PDB
p.M404V UBA Italy m Probable AD S 52 PDB
p.P438L UBA Belgium f Probable AD F 67 SALS
f Probable AD F 75
Protein domains were assigned as described previously (van der Zee et al., 2014). More information on the AD patients carrying the mutations can be found in the columns
“origin,” “gender,” clinical diagnosis,” “family history” (sporadic [S] or familial [F]), and “age at onset.” The column “previously reported” shows the variants that were pre-
viously described in context of ALS, FTLD, or PDB (Le Ber et al., 2013; Rea et al., 2013; Rubino et al., 2012). Rare variants p.L268V and p.P387L were carried by the same AD
patient, originating from Italy.
Key: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; F, familial; f, female; FTLD, frontotemporal lobar degeneration; m, male; PB1, Phox and Bem1p; PDB, Paget
disease of the bone; PEST1, proline (P), glutamic acid (E), serine (S), and threonine (T) (PEST); S, sporadic; SALS, sporadic amyotrophic lateral sclerosis; SQSTM1, sequestosome
1; UBA, ubiquitin associated.
a Carried a known pathogenic mutation for AD (presenilin-1 [PSEN1] p.L392V).
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In this study, we have investigated the presence of common and
rare exonic variants in SQSTM1 in a total of 1361 early-onset and/or
familial AD patients and 2348 healthy individuals from 7 countries
across Europe. We detected a total of 61 variants in the exonic re-
gion of SQSTM1, of which the majority (n ¼ 57) were rare and
identiﬁed in only one or few individuals, suggesting a high genetic
variability of SQSTM1. We identiﬁed 5 variants that were not pre-
sent in our tested control population of which one (p.P438L) was
earlier described in the context of ALS (Rubino et al., 2012). Two
variants, (p.P29S and p.L268V) that were only identiﬁed in our AD
population, were excluded from publicly available databases
(Exome Variant Server, dbSNP, and Ensemble). Overall, however,
rare SQSTM1 variants were identiﬁed at equal frequencies in AD
patients and control individuals across populations (cumulative
frequencies ranging from 0.9% to 2.8%), suggesting no major causal
role for rare SQSTM1 variants in the pathogenesis of early-onset AD.
Of note, 2 of the variants we identiﬁed in patients only are known to
be pathogenic in PDB (Rea et al., 2013). Other known pathogenic
mutations for PDB were identiﬁed both in AD patients and control
individuals, and the frequency of these mutations corresponded to
the prevalence of PDB in the general population (1%e2%) (Ralston
et al., 2008). Unfortunately, our patient cohorts were notFig. 2. Common variant meta-analysis of the Flanders-Belgian and European early-
onset dementia cohorts: p.D292¼.systematically screened for clinical or radiological signs of PDB,
precluding further inferences.
Two AD patients harbored multiple rare variants in SQSTM1, and
2 patients carried both a PSEN1 and a SQSTM1 mutation. Double
SQSTM1 mutations were described earlier in the context of PDB
(Collet et al., 2007) and ALS (Shimizu et al., 2013). This could imply
that individual mutation burden of SQSTM1 could modify disease
susceptibility; however, additional systematic screening efforts are
required to investigate this further. Of note, 2 control individuals
also carried several SQSTM1 variants.
Resequencing of the full coding region of SQSTM1 revealed only 4
variants at individual frequencies >1%. Two common synonymous
variants, which are in strong pairwise LD, showed marginal evi-
dence of association with AD. These variations exert no obvious
effect on protein, but in silico predictions (MutationTaster, Schwarz
et al., 2014) suggest that they might introduce a splice site. Both
SNPs are in pairwise LDwith the GWAS top SNP rs72807343 (D’¼ 1),
although a large difference in frequency of occurrence was found
(r2 ¼ 0.011). However, the observed association appeared limited to
the Flanders-Belgian population and would not have survived
correction for multiple testing. Moreover, although the GWAS top
SNP was not covered by the genotyping assays in the present study
because of its localization outside the coding sequence of SQSTM1, it
had previously been genotyped by custom Illumina SNP chip in the
replication stage of an AD GWAS meta-analysis in part of our
Flanders-Belgian late-onset AD cohort (887 AD patients and 674
control individuals; overlap with the patient cohort described here
n¼ 343) (Lambert et al., 2013). In this subset of the Flanders-Belgian
population, rs72807343 did not reveal statistical association with
AD (OR ¼ 0.83 [95% CI ¼ 0.45e1.54], allelic p ¼ 0.56).
One low-frequent missense variant, p.E274D (MAF 2%), showed
a trend toward association in the Flanders-Belgian AD cohort.
Interestingly, this variant showed tentative evidence of association
in the International Genomics of Alzheimer’s Project exome chip
data analysis, which is performed on late-onset AD patients and
control individuals (S. van der Lee and C.M. van Duijn, personal
communication 2014). Nevertheless, when meta-analyzing the EU
EOD cohort, this trend toward association disappeared. Of note, the
Flanders-Belgian patient group had a higher average onset age than
the EOD cohorts because of inclusion of familial AD patients with
onset >65 years. Conceivably, this might explain why we cannot
conﬁrm the Flanders-Belgian trend toward association between
SQSTM1 variants and AD in the EU EOD cohort, which should have
sufﬁcient statistical power (>90%) to detect a risk allele with MAF
2% and OR 1.67 at alpha level of 0.05. In line with this, the GWAS
association at SQSTM1 was predominantly based on late-onset AD
(Lambert et al., 2013).
E. Cuyvers et al. / Neurobiology of Aging 36 (2015) 2005.e15e2005.e22 2005.e21In conclusion, in this European study on AD patients with early-
onset and/or positive family history, thus likely to have an
augmented genetic risk proﬁle, we observed 61 variants in the
exonic region of SQSTM1 (comprising only 8 exons), both in patients
and in cognitively healthy individuals, suggesting a high genetic
variability of the gene. We cannot exclude a role of SQSTM1 genetic
variability in late-onset AD, but our data indicate that common and
rare coding variations in SQSTM1 do not play a major role in the
etiology of early-onset AD.
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